Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Historic Operating Leases for Arcus Biosciences (RCUS) over the last 3 years, with Q3 2022 value amounting to $119.2 million.

  • Arcus Biosciences' Operating Leases rose 13055.13% to $119.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $119.2 million, marking a year-over-year increase of 13055.13%. This contributed to the annual value of $116.9 million for FY2021, which is 66682.41% up from last year.
  • According to the latest figures from Q3 2022, Arcus Biosciences' Operating Leases is $119.2 million, which was up 13055.13% from $121.3 million recorded in Q2 2022.
  • In the past 5 years, Arcus Biosciences' Operating Leases ranged from a high of $121.3 million in Q2 2022 and a low of $14.7 million during Q1 2021
  • Over the past 3 years, Arcus Biosciences' median Operating Leases value was $83.5 million (recorded in 2021), while the average stood at $75.8 million.
  • Data for Arcus Biosciences' Operating Leases shows a peak YoY increase of 68073.58% (in 2022) and a maximum YoY decrease of 13055.13% (in 2022) over the last 5 years.
  • Arcus Biosciences' Operating Leases (Quarter) stood at $15.2 million in 2020, then soared by 666.82% to $116.9 million in 2021, then increased by 1.97% to $119.2 million in 2022.
  • Its Operating Leases was $119.2 million in Q3 2022, compared to $121.3 million in Q2 2022 and $114.8 million in Q1 2022.